M ETH O DS Figure 1. Study Design

> r
@ Linda R Duska | LRD health | NTRO D) UCTI O N * This multicohort phase I/II trial, evaluated the safety and efficacy of Distaserepeciictcchartsd aera oe
x D i j (excep coh O ( Fla 3 cohort [e] t)
Dax Mintek) Ushe) @uva ealth.org + Dysregulation of Enhancer of Zeste Homolog 2 (EZH2) activity critically affects cancer progression and drug resistance, especially Spacey te mercer habeas gees eae vont eorecnae M3)
in tumors with AT-Rich Interaction Domain 1(ARID1A) mutations (ARID1Amut)!2 tela i PE fafablovibigdhrea toces (Egatex) } me | OCCC: ovarian clear cell carcinomat Stage 1: Stage 2: Stage 2a Stage 2b
a ‘ : A Baie . a . = otcome ore ee ee eee . e patients received one of the following three doses (Figure 1): a ( n=10 plus n=19
. . . (eter eae a Senne ome ee a geal bad ete pends eae ig aca ead _ — 350 mg continuous once daily (OD) dose in a dose expansion stage x s 3 | EC: endometrial carcinomat per cohort except per cohort Close RP2D 200 mg: n=10 Dose 200 mg: n=10
rs | se (@) se (@) ] mM iZa 10 n carcinoma subtypes.* Over 50% C. lave Al A mutations, leading to protein loss and shorter progression-free : ti Si 5 2-St desi zs M4, M7 (n=20) cohort and open per cohort optimization per cohort
survival and overall survival (OS). Current platinum-based chemotherapy has limited benefits for these patients! °* ede nh a ial “ = a z nt hs eel tel 24/10 ORR dose optimization 300 mg: n=10 expansion in 300 mg: n=10
Bs Serer Pa : ; an z . — To evaluate an optimal dose of tulmimetostat monotherapy, the phase 7 ia in cohorts per cohort M2/M3 cohorts per cohort
+ Increase in is associated with de: e and disease-fre a metrial Cancer (EC).°A . ae Single- r
1 1 1 1 lit n Bane abst te Seabed bis Giigieeat) CS cus! ¢) Hee SMM n Sila all Causa Deel study design was updated to assess two additional doses of 300 mg and pina eset aocenraliment
U | @ rs | e WI ] n ] ] Oo r 36-40% of ECs have ARID1A mutations, which are associated with a worse prognosis in patients with EC® saana sHtncne ODaees n=20 PTCL and DLBCLt P A
ie@anes inn AR A A Fy ee > inhibitio - f; ARRAN @ Atle 7 ast Stage 2b initiates once either of the Stage 2a
Cancers bearing AR/D1A mutations display increased sensitivity to EZH2 inhibition suggesting a potential synthetic lethality + Dose optimization was conducted in two stages, Stage 2a and Stage 2b. < s L predefined protocol criteria’ are met

approach to target AR/D1Amut OCCC and ECs'?”

tu | m i aa etostat DZR1 23/C P| -0209 In each cohort, Stage 2a comprises 20 patients, randomized 1:1 between 1. 22/10 ORR in a dose cohort
+ Tulmimetostat (DZR123/CPI-0209), a next-generation, oral, dual EZH2/EZH1 inhibitor currently under investigation, elicits more 200 mg and 300 mg; Stage 2b enrolled up to 20 more patients in each cohort if 2. 1/10 ORR in a specific cohort

5 a 5 anti-tumor activity versus first-generation EZH2 inhibitors in preclinical studies, due to slower off rate and increased on-target predefined protocol conditions were met in Stage 2a (supported by totality of data)
] n pat ] e n ts with ARID 1A =—M U tated resiélemee ime! * Key eligibility criteria included adult patients with disease who had progressed $ SOO ORR In 200 mecohet and
+ This phase I/II study aims to evaluate the anti-tumor activity and safety of tulmimetostat in advanced solid tumors and lymphomas. '” on applicable prior lines of treatment and met other tumor-specific inclusion (supported by totality of data)
. . We report here the update and safety of tulmimetostat in AR/D1Amut OCCC and EC patients from dose expansion and criteria as per protocol, and as listed on ClinicalTrials. gov
We here the updated efficacy and of tulmii in ARID1Amut OCCC and EC pati from d pansion and iteri |, and as listed on ClinicalTrial .
eee a 5 = *Patients in all cohorts have progressive disease with applicable prior lines of therapy, ‘Histologically or cytologically confirmed progressive tumor, Including GCB-DLBCL, *Stage 2b enrollment will be initiated if criterion in Stage 2a are
Ov rs | a rs | n Cc | ea r ce | | Cc rs | rc ] n Oo mM rs | Oo r optimization part of the trial'®""""? * Primary endpoint was objective response rate (ORR) and secondary endpoint met as follows: Criteria 1 is met (22 responses in a dose cohort); or Criteria 2 is met (21 response in a specific dose cohort). Stage 2b enrollment may be initiated based on totality of safety, efficacy, and exposure-response data of that
cohort; or if Criteria 3 is met (no response in 300 mg cohort and 22/10 ORR in 200 mg cohort). Stage 2b may be opened for the 300 mg dose level based on totality of safety, efficacy, and exposure-response data
was safety DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell, ORR, objective response rate; PTCL, peripheral T-cell lymphoma; RP2D, recommended Phase |! dose
endometrial carcinoma
R ES U LTS Figure 2. Best percentage change from baseline in target lesions across all dose levels (per RECIST 1.1) Table 3. Patients experiencing at least one TEAE possibly related (TRAE) to tulmimetostat
. . . a occc EC
. Ase yen ‘ oe eproument Into the talmimetostst oy Mod eaten ‘oot eee: nt 62%) EC one 21 (21, , 70 M2 (OCCcC) M3 (EC) Events (n[%J) 200 mg 300 mg 350 mg 200 mg 300 mg 350mg
F 1 D a S\/R 3 4 an patients, in an cohorts respectively. Most patients in an cohorts receive: 60-4 (N=20) (N=21) (N=14) (N=10) (N=21) (N=11)
Linda is Duska, Kalyan Banda, Ana Oaknin, Vincent Ribrag, 23 prior lines of therapy (Table 1) 50 TRAE 18 (90.0) 21 (100) 14 (100) 8 (80.0) 21 (100) 11 (100)
Antonio Gonzalez Martin,® Nehal J Lakhani,° Jung-Yun Lee,’ * In EC, majority of patients (64-81%) enrolled had an ECOG performance status of 1. Notably, a numerically higher 2 Grade 23 9 (45.0) 9 (42.9) 8 (57.1) 4 (10.0) 12 (57.1) 5 (45.5)
“3 . 9 . : : : 10 number of patients in 200 and 300 mg dose arms had ECOG status 1 compared with the 350 mg arm (Table 1) g 40 Serious TRAE 3 (15.0) 2 (9.5) 3 (21.4) 7) 5 (23.8) 3 (27.3)
Alok Tewari, Susana N Banerjee, Maria-Pilar Barretina-Ginesta, a ole TRAE leading to dose modification 9 (45.0) 14 (66.7) 11 (78.6) 6 (60.0) 16 (76.2) 10 (90.9)
A 5 ali 4 5 2 4 13 Table 1. Baseline and disease characteristics 5 TRAE resulting in dose reduction 6 (30.0) 5 (23.8) 8 (67.1) 2 (20.0) 10 (47.6) 5 (45.5)
Valentina Boni, Mehdi Brah mi, Lauriane Eberst, cco ewer 5 204 TRAE leading to dose interruption 8 (40.0) 13 (61.9) 1071.4) 5 (50.0) 41 (52.4) 6 (54.5)
5 i ri D | . . n .
Jae Hoon Kim,'* Nicoletta Colombo, '* Domenica Lorusso, '*"” 200 mg 300 mg 360 mg 200 mg 300 mg 350 mg 2 io _ TRAE leading to treatment discontinuation 2(10.0) 0 2 (143) 1 (10.0) 2(9.5) 1.1)
. 18 18 oe 18 (N=20) (N=21) (N=14) (N=10) (N=21) (N=11) & | | Pt Data are reported asn (%) for patients in the safety analysis eS Data cutoff March 1, 2025 EC, endometrial carcinoma, OCCC, ovarian clear cell carcinoma;
Nicola Faulhaber, '® Lennart Kann,'® Anjali Thakur, Baseline characteristics a) ns mmay 1 emhmmehememE EEE SIS
Charles Drescher’? Age (¥) ange) 50 (38-69) 55 (38-76) 54 (39-67) 62 (49-86) 64 (45-77) 67 (57-82) 2 “104 | | Figure 4, Frequently reported TEAEs (>15% either indication) possibly related (TRAEs) to tulmimetostat
. . an . Time since initial : -20 M2(OCCC) M3 (EC)
University of Virginia Health System, Charlottesville, VA, USA; 2Seattle Cancer Care diagnosis (y) 2.2 (0.4-7.6) 2.2 (0.8-6.6) 3.5 (0.6-8.8) 4.1 (1.0-13.2) 3.2 (0.6-11.2) 3.2 (0.6-7.0) 3 50 ||| 8 70 6 50 40 3 2 10 oO 0 10 2 30 40 50 60 70 80
Alliance, Seattle, WA, USA; Medical Oncology Service, Vall d’Hebron Institute of ll ie 5 ao. — a ————
, A Arno I £ ee
Oncology, Vall d Hebron Barcelona Hospital Campus, Barcelona, Spain, Gustave Lines of prior cancer = sol —_
Roussy, DITEP (Institut de Cancerologie Gustave-Roussy), Villejuif, France; °University therapy, n(%) ro : _— = — Thrombocytopenia
. . : : : : 1 2 (10.0 295 4 (28.6 1 (10.0 5 (23.8 2(18.2 a
Clinic of Navarra, Madrid, Spain; START Midwest, Grand Rapids, MI, USA; "Yonsei 2 pie aon perp ae aren pe EB 604 l — Anaemia
Cancer Center and Severance Hospital, Yonsei University College of Medicine, Seoul, Ls) ab abe aia, pay are sae, aioe % -70 —_xx___ a [—
South Korea; ®Dana Farber Cancer Institute, Boston, MA, USA; Royal Marsden NHS See Rexeaenes ™ e0- CO _ _  _ — Diarrhoea ————=—u
Foundation Trust and Institute of Cancer Research, London, UK; ‘°University Hospital Status, n(%) °0 _!
F F Peer i F P F : F 0 10 (50.0) 11 (52.4) 6 (42.9) 2 (20.0) 4 (19.0) 4 (36.4) 790) —— Vomitin [oe
of Girona, Girona, Spain; : NEXT Oncology Madrid, University Hospital Quironsalud, Fi 10 (60.0) 40 (47.6) 8 (67,1) 8 (80.0) 47 (81.0) 7 (636) soo! ————EeEEEeEeEeeee 9g —
Madrid, Spain; '*Centre Léon Bérard, Lyon, France; '*Strasbourg Europe Institut of EC, endometrial carcinoma: ECOG, eastern cooperative oncology group, OCC, ovarian clear cell carcinoma; y, years. Values have been reported as n(%) unless othemise specified . * _ 00 asa pysgeilsia
14 : . a fs OCCC Starting dose (mg): ™ 200mg ™ 300mg M@ 350mg EC Starting dose (mg): = 200mg m300mg 350mg Se _—$—$_——
Cancerology, Strasbourg, France; “Gangnam Severance Hospital, Yonsei University, Efficacy Data cutoft March 1, 2028 "Complete response reported in target lesion SSS
Seoul, Republic of Korea; ‘SEuropean Institute of Oncology, IRCCS, Milan, Italy; EC, endometrial carcinoma, OCCC, ovarian clear cell carcinoma, RECIST, response evaluation criteria in solid tumours. SND Nausea _————
16 ; ; ; A ; ; ; ; * In OCCC, the highest confirmed ORR was reported for 200 mg dose (25%) and in the EC cohort, the highest confirmed . . | LL ——— eae
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ORR was reported for 350 mg dose (36.4%) (Table 2) Figure 3. Treatment duration and response assessment in the M2/M3 cohorts ;
17 i i i + 18 3 . === Alopecia eT
Italy; '-Humanitas San Pio X, Milan, Italy; '’*MorphoSys GmbH, Planegg, Germany; . . 5 . . * : > x ————— ————
9Swedish C Institute. Seattle. WA. USA * Inthe EC cohort, all responders experienced deep responses, with more than 50% reduction in target lesions. For the = = = — .
weaisn Cancer Institute, oeattle, , . OCCC cohort reductions ranged from 30% to 100% (Figure 2) = ° = =uuuss=== Decreased appetite =
= 5 = x ————= a
* Of the 55 patients with OCCC (M2), 22 (40%) were on treatment for more than 5 months. Among these, 4/22 (18%) _——<———————————— id L
remained on treatment at the time of data cutoff. For EC of 42 patients, 13 (31%) were on treatment for more than ——SSSS - x x —EEee Headache —
5 months. Among these, 8/13 (62%) remained on treatment (Figure 3) o = = 5 .
| . a x —= Neutropenia —
Table 2. Best confirmed and unconfirmed response per dose in OCCC and EC patients oO == = — —
occc EC ——— x =mmmms Weightdecreased = Samm
2° * as creme:
200 mg 300 mg 350 mg 200 mg 300 mg 350 mg -—$s. ° xx
Antitumor activity in terms of objective responses and disease n(%) (N=20) (N=21) (N=14) (N=10) bc men) —. .« x = Aspartate AT increased mn
eo ge : Best confirmed ) () () () 1(48 () o 4
stabilization were observed in both OCCC and EC oe cones vesponse oe aa — ; —
CR Best confirmed / a a a a 4 (48) 411) —,% x x — Asthenia —
Tumor regression was observed for both cohorts (OCCC and EC), with unconfirmed response —s, —_
t . to 100% Best confirmed response 5 (25.0) 3 (14.3) 1 (7.1) (e) 3 (14.3) 4 (36.4) ——————————————— | J Constipation
hae “Wee dow up , p 40% « patients with OCCC and 31% of ia ae ered sesponse 7 (35.0) 3(14.3) 4 (28.6) 1 (10.0) 3(14.3) 3 (27.3) SS eee | ] | =
cross three dose conorts © OT patients WI an 0 O _~=<—— x * — Epistaxis —=
. . . , P Best confirmed response 5 (25.0) 314.3) 1(7.1) (0) 4 (19.0) 4 (36.4) —————_—~_— — es eel
patients with EC remained on treatment for more than 5 months ORR Past contac I a
x —
. (CR + PR) ereonimecieencnes 7 (35.0) 3 (14.3) 4 (28.6) 1 (10.0) 4 (19.0) 4 (36.4) o ~=_— ——4 Abdominal pain
Safety data of tulmimetostat at 200 mg showed an acceptable safety Incase of confirmed == a
7 . . . = —". i j
profile in patients with AR/D1Amut OCCC and EC compared to 300 and so CRIPR SCSo) MEH) 720) 8 (80.0) Ss) 327.3) * mee Alanine ATincreased = fmm
350 mg doses PE 7 (35.0) 10 (47.6) 4 (28.6) 7 (70.0) 6 (28.6) 3 (27.3) Al Blood creatinine increased ees
These updated findings in heavily pretreated patients with AR/D1Amut PD 5 (25.0) 8 (38.1) 6 (42.9) 1 (10.0) 9(42.9) 3 (27.3) 0 7 2 8 4 5 6 7 8 9 1 1 42 18 14 45 16 17 18 19 2 21 22 23 24 25 26 27 28 29 cough
. . . . p p 4 - - - - — ‘oug!
OCCC or EC support ongoing investigation of the dual EZH2/EZH1 eae aaa 16.0) C T@ay) 205) 101) OCCC Starting dose (mg): ™ 200mg M™ 300 imp Ee Barina dose (mg): ™ 200mg 300mg m350mg — || Grade ss
: mg mg mg : 2
inhibitor tulmimetostat Data cut-off: March 1, 2025. *Per RECIST v1.112. All values have been reported as n(%). CR, complete response, EC, endometrial carcinoma, OCCC, ovarian clear cell carcinoma, Assessment: =Complete response @ Partial response A Stable disease Progressive disease Deeth _» Treatment ongoing — Dizziness — 200m
ORR, objective response rate; PD, progressive disease; PR, partial response, RECIST, response evaluation criteriain solid tumours; SD, stable disease. Data cutoff March 1, 2025 | ‘all moe
Ss f EC, endometrial carcinoma; OCCC, ovarian clear cell carcinoma Lymphocyte count decreased — 9
a ety = | 300 mg
Grade 23
+ Almost all patients experienced at least one treatment-emergent adverse events (TEAE) irrespective of causality in both Safety Neutrophil count decreased a0
ees m
OCCC and EC cohorts * Most common TEAEs (all grades) possibly related to tulmimetostat (TRAEs) included fatigue, thrombocytopenia, anemia, i All grade
- : : 5 ° , “a : ee Platelet t di d
To download a copy of this poster, visit the web at: Serious TEAEs were frequent in OCCC 350 mg 57.1% (8/14) and EC 350 mg 72.7% (8/11) diarrhea, vomiting, dysgeusia, nausea, and alopecia (Figure 4) jatelet count decrease ee | 350 mg
Scan to https: //tinyurl.com/LindaR3102 — Grade 23 for at least one TEAE was common in OCCC 350 mg 78.6% (11/14) and EC 300 mg 90.5% (19/21), while — About 15% in OCCC and 19% in EC had a serious TRAE with 47% in OCCC and 43% in EC having at least one | —— | Grade 23
benin me grade =3 serious TEAEs were common in OCCC 350 mg 57.1% (8/14) and EC 350 mg 63.6% (7/11) dose arms TRAE of grade 23 (Table 3) - Pruritus | 350 mg
e . . . .
Post Copies of this poster obtained through quick response — Highest incidence of TEAEs requiring dose reductions occurred in OCCC 350 mg 64.3% (9/14) and in EC 300 mg — Most grade 23 TRAEs were hematologic and more common with 300 and 350 mg doses. High incidence of grade Rash All grade
oster (QR) code are for personal use only and may not be 52.4% (11/21) >3 anemia were observed in 350 mg OCCC (50%) and 300 mg EC (29%), thrombocytopenia in 350 mg OCCC (29%) = —_a
reproduced without written permission of the authors. — Highest treatment discontinuations due to TEAEs were reported in the OCCC 350 mg 14.3% (2/14) and in and 300 mg EC (10%). Diarrhea, another common grade 23 TRAE, was reported in 300 mg OCCC (24%) and 350 mg
EC 200 mg 20.0% (2/10) cohorts. No TEAEs led treatment discontinuations in the OCCC 300 mg cohort EC (18%) (Table 3 and Figure 4) TEAL trectmatherteigent adversoevent, TRAE TEAL possbiyreleiedtotummiietccet ene: RS enenen cieer ced eatenen®
References Acknowledgments Disclosures
1. Bitler BG, et al. Nat Med 2015;21((3):231-38. 5. Roh JWet al. Cancer Biol Ther. 2020:21(2):147-156. 9. Wu R, et al. Cancer Res 2021;81 (Suppl 13). The aes thank epdens ould init acy aeeiihetamiee see aaihne auc ‘ Be Linde Dale rors institution research funds frm Mien Bicke ch ACs clea centers DERM a Sie,
. . . . 4 . 7 a 10. ClinicalTrials.gov. NCT04104776 www.clinicaltrials.gov/study/NCT041 04776 [Accessed 15 May, 2025]. Investigators. jé authors than snwinl Kumar, jarmD, an ijl Joseph, Cc, botn of jovarils erulean arma, Genentect oche, jaxoomii ine, Leap jerapeutics, Ludwig Institute for Cancer Researcn, Merck,
This study was sponsored by Novartis Pharma AG, Basel, Switzerland. 2. Eich ML, et al. Cancer Res 2020;80(24):5449-58. Gh. GS Keo etal GOES: hs [RED CHIE HE, 41. Oaknin A. et al. ESMO 2024, Poster-748P. Healthcare Pvt Ltd (Hyderabad, India), for providing medical editorial assistance in the Millennium, Morab, Morphotek, Novartis, Pfizer, Syndax, and Tesaro. Institution payments for her role in the Monitoring and
Post ted at: The A . Society of Clinical O (ASCO) A | Meeti 3. Maeda D, et al. Int J Mol Sei 2010;11(12):5120-28. 7. Lid, et al. J Clin Invest 2020;130(5):2712-26. wm eetah nm , 1 RGSS) an Pot ou. preparation of this poster, in accordance with Good Publication Practice (GPP3) guidelines Advisory Boards of Innovio, Aegenus, and Merck, and personal fees from Daiichi Sankyo.
oster presented al: [ne American society of Clinical Oncology nnua! Meeting; 4. Liu Z, et al. J Ovarian Res 2024;17(1):39. 8. Lakhani Nu, et al. J Clin Oncol 2021;39 (Suppl 15):3104. Sahoo bE PET

May 30 - June 3, 2025; Chicago, IL, US.

